CVS Health Declines To Add Gilead's Steeply Priced New HIV Prevention Drug To Its Plans

Why is Fed Governor Lisa Cook fighting her firing? How will end of ‘de minimis’ affect online shopping? What caused Affirm's stock to surge after Q4? Why did Tesla's European sales plunge again? How is Nvidia impacted by China market restrictions? Why are Uber and Lyft backing California driver union bill? What led to Ssense filing for bankruptcy protection?

CVS Health Declines To Add Gilead's Steeply Priced New HIV Prevention Drug To Its Plans

benzinga.com/news/health-care/25/08/47257284/cvs-health-declines-to-add-gileads-steeply-priced-new-hiv-prevention-drug-to-its-plans

CVS Health Inc. (NYSE:CVS) said it will not add Gilead Sciences Inc.’s (NASDAQ:GILD) new HIV prevention drug Yeztugo to its commercial plans.
In June, the U.S. Food and Drug Administration (FDA) approved Gilead Sciences’ Yeztugo (lenacapavir) as pre-exposure prophylaxis (PrEP) to reduce…

This story appeared on benzinga.com, 2025-08-21 12:54:37.